checkAd
    Startseite > Aktien > Tryp Therapeutics > Nachrichten
    Tryp Therapeutics Aktie
    0,0839
     
    EUR
    -23,73 %
    -0,0261 EUR
    Letzter Kurs 01.11.22 Tradegate
    0,0973
     
    EUR
    11.000 STK
    Geldkurs 01.11.22
    0,1224
     
    EUR
    9.000 STK
    Briefkurs 01.11.22
    ISIN: CA89854F1062 · WKN: A2QKZP · SYM: 8FW · Kanada

    Neueste Nachrichten

    Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
    01.05.24 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
    24.04.24 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
    12.03.24 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
    11.12.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
    20.11.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million
    02.11.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Announces Closing of Private Placement of Unsecured Convertible Debentures for Gross Proceeds of AUD$175,000
    11.10.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Announces Private Placement of Unsecured Convertible Debentures for Gross Proceeds of up to AUD$175,000
    04.10.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Announces Jason Carroll as New Chief Executive Officer
    03.08.23 · Accesswire · Tryp Therapeutics
    With Great Sadness Tryp Announces the Passing of David Tousley, Director
    02.08.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Receives Confirmation From FDA To Proceed With Phase 2A Clinical Trial in Patients With IBS at Massachusetts General Hospital
    13.07.23 · Accesswire · Tryp Therapeutics
    Tryp Therapeutics Submits Investigational New Drug (IND) Application to US FDA for Planned Phase 2a Clinical Trial in Patients With IBS at Massachusetts General Hospital
    24.05.23 · Accesswire · Tryp Therapeutics